The coronavirus pandemic has affected the whole world and its effects continue to be felt. The measures taken so far have been aimed at preventing the spread of the disease. The European Medicines Agency has given permission for a drug that has been used only for emergencies to be used for the treatment of Covid.
Developed by the German pharmaceutical giant Pfizer, the drug called Paxlovid was previously authorized to be used in emergencies by the American Food and Drug Administration (FDA). This pill helps people who come into contact with the disease be treated before their condition worsens and they develop serious symptoms.
Pfizer relies on its own pill
Especially with the Omicron variant, the treatment of coronavirus once again came to the point of blockage. Because the two antibiotics that were effective in the previous variants were quite ineffective this time. Thanks to the approval received at this time, one more step has been taken to prevent the pandemic from getting out of control again.
The reasons why Pfizer’s Paxlovid is considered so important is because of its efficiency, relatively low cost, and ease of authorization. The test results of the drug are also remarkable. The drug, which prevents the virus from replicating and multiplying, reduces the risk of being hospitalized and death by 89%.
Pfizer is ready for production
Pfizer had previously agreed with the United States for 10 million doses for this drug, and agreed to pay $5.29 billion in this agreement. At the end of last year, in the statement made by Pfizer, it was announced that an additional supply of 2.5 million doses would be provided to the United Kingdom. The first agreed amount was 250 thousand doses.
SVB Leerink analyst Geoffrey Porges said he expects the drug to generate $24.2 billion in revenue by 2022. Pfizer CEO Bourla stated that the company could produce 80 million doses in 2022. The drug, which was previously approved for emergency, is now available in Europe.
30184
